Drs. Ron and Waksman and Aernoud Fiolet discuss the LoDoCo 2 trial, which was presented at the European Society of Cardiology 2020 virtual congress on Aug. 31, 2020. The study found that low-dose colchicine reduces the risk of cardiovascular events in patients with chronic coronary disease.

The European Society of Cardiology 2020 virtual congress included three studies that examined the role of colchicine, a gout medication, in treating coronary artery disease.

Watch the interview